CVS: Cvs Health Corp Financial Statements
Balance sheet, income statement, and cash flow statements for Cvs Health Corp (CVS).
$56.49B Market Cap.
CVS Market Cap. (MRY)
CVS Shares Outstanding (MRY)
CVS Assets (MRY)
Total Assets
$253.22B
Total Liabilities
$177.49B
Total Investments
$31.34B
CVS Income (MRY)
Revenue
$372.81B
Net Income
$4.61B
Operating Expense
$42.88B
CVS Cash Flow (MRY)
CF Operations
$9.11B
CF Investing
-$7.61B
CF Financing
-$1.14B
CVS Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $253,215,000,000 (1.40%) | $249,728,000,000 (9.40%) | $228,275,000,000 (-2.03%) | $232,999,000,000 (0.99%) |
Assets Current | $68,645,000,000 (1.16%) | $67,858,000,000 (3.39%) | $65,633,000,000 (9.37%) | $60,008,000,000 (6.46%) |
Assets Non-Current | $184,570,000,000 (1.48%) | $181,870,000,000 (11.82%) | $162,642,000,000 (-5.98%) | $172,991,000,000 (-0.78%) |
Goodwill & Intangible Assets | $118,595,000,000 (-1.59%) | $120,506,000,000 (17.05%) | $102,953,000,000 (-4.80%) | $108,147,000,000 (-2.30%) |
Shareholders Equity | $75,560,000,000 (-1.18%) | $76,461,000,000 (6.98%) | $71,469,000,000 (-4.80%) | $75,075,000,000 (8.19%) |
Property Plant & Equipment Net | $28,937,000,000 (-4.92%) | $30,435,000,000 (-1.01%) | $30,745,000,000 (-3.98%) | $32,018,000,000 (-3.95%) |
Cash & Equivalents | $8,586,000,000 (4.76%) | $8,196,000,000 (-36.69%) | $12,945,000,000 (37.60%) | $9,408,000,000 (19.79%) |
Accumulated Other Comprehensive Income | -$120,000,000 (59.60%) | -$297,000,000 (76.50%) | -$1,264,000,000 (-230.98%) | $965,000,000 (-31.75%) |
Deferred Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Investments | $31,341,000,000 (19.27%) | $26,278,000,000 (10.07%) | $23,874,000,000 (-8.68%) | $26,142,000,000 (9.78%) |
Investments Current | $2,407,000,000 (-26.14%) | $3,259,000,000 (17.31%) | $2,778,000,000 (-10.88%) | $3,117,000,000 (3.90%) |
Investments Non-Current | $28,934,000,000 (25.70%) | $23,019,000,000 (9.12%) | $21,096,000,000 (-8.38%) | $23,025,000,000 (10.63%) |
Inventory | $18,107,000,000 (0.45%) | $18,025,000,000 (-5.58%) | $19,090,000,000 (7.49%) | $17,760,000,000 (-3.98%) |
Trade & Non-Trade Receivables | $36,469,000,000 (3.53%) | $35,227,000,000 (29.15%) | $27,276,000,000 (11.65%) | $24,431,000,000 (12.37%) |
Trade & Non-Trade Payables | $15,892,000,000 (6.68%) | $14,897,000,000 (0.40%) | $14,838,000,000 (18.29%) | $12,544,000,000 (12.62%) |
Accumulated Retained Earnings (Deficit) | $62,837,000,000 (2.00%) | $61,604,000,000 (9.23%) | $56,398,000,000 (2.72%) | $54,906,000,000 (10.61%) |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Tax Liabilities | $3,806,000,000 (-11.71%) | $4,311,000,000 (7.35%) | $4,016,000,000 (-35.95%) | $6,270,000,000 (-7.71%) |
Total Debt | $82,920,000,000 (4.45%) | $79,385,000,000 (12.23%) | $70,732,000,000 (-6.93%) | $75,999,000,000 (-10.63%) |
Debt Current | $7,494,000,000 (59.01%) | $4,713,000,000 (36.37%) | $3,456,000,000 (-40.93%) | $5,851,000,000 (-17.34%) |
Debt Non-Current | $75,426,000,000 (1.01%) | $74,672,000,000 (10.99%) | $67,276,000,000 (-4.09%) | $70,148,000,000 (-10.03%) |
Total Liabilities | $177,485,000,000 (2.54%) | $173,092,000,000 (10.60%) | $156,506,000,000 (-0.71%) | $157,618,000,000 (-2.11%) |
Liabilities Current | $84,609,000,000 (6.84%) | $79,189,000,000 (14.07%) | $69,421,000,000 (2.38%) | $67,807,000,000 (9.34%) |
Liabilities Non-Current | $92,876,000,000 (-1.09%) | $93,903,000,000 (7.83%) | $87,085,000,000 (-3.04%) | $89,811,000,000 (-9.28%) |
CVS Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $372,809,000,000 (4.20%) | $357,776,000,000 (10.95%) | $322,467,000,000 (10.39%) | $292,111,000,000 (8.71%) |
Cost of Revenue | $321,408,000,000 (5.95%) | $303,345,000,000 (13.20%) | $267,965,000,000 (11.66%) | $239,991,000,000 (9.26%) |
Selling General & Administrative Expense | $41,606,000,000 (4.45%) | $39,832,000,000 (4.24%) | $38,212,000,000 (3.22%) | $37,021,000,000 (5.37%) |
Research & Development Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Operating Expenses | $42,885,000,000 (5.40%) | $40,688,000,000 (-12.59%) | $46,548,000,000 (19.94%) | $38,810,000,000 (10.46%) |
Interest Expense | $2,958,000,000 (11.29%) | $2,658,000,000 (16.22%) | $2,287,000,000 (-8.63%) | $2,503,000,000 (-13.90%) |
Income Tax Expense | $1,562,000,000 (-44.31%) | $2,805,000,000 (85.88%) | $1,509,000,000 (-40.78%) | $2,548,000,000 (-0.82%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | $4,586,000,000 (-45.20%) | $8,368,000,000 (93.39%) | $4,327,000,000 (-45.84%) | $7,989,000,000 (11.08%) |
Net Income to Non-Controlling Interests | -$28,000,000 (-216.67%) | $24,000,000 (50.00%) | $16,000,000 (233.33%) | -$12,000,000 (-192.31%) |
Net Income | $4,614,000,000 (-44.70%) | $8,344,000,000 (93.55%) | $4,311,000,000 (-46.12%) | $8,001,000,000 (11.45%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | $4,614,000,000 (-44.70%) | $8,344,000,000 (93.55%) | $4,311,000,000 (-46.12%) | $8,001,000,000 (11.45%) |
Weighted Average Shares | $1,259,000,000 (-2.02%) | $1,285,000,000 (-2.06%) | $1,312,000,000 (-0.53%) | $1,319,000,000 (0.76%) |
Weighted Average Shares Diluted | $1,262,000,000 (-2.17%) | $1,290,000,000 (-2.49%) | $1,323,000,000 (-0.45%) | $1,329,000,000 (1.14%) |
Earning Before Interest & Taxes (EBIT) | $9,134,000,000 (-33.85%) | $13,807,000,000 (70.31%) | $8,107,000,000 (-37.89%) | $13,052,000,000 (3.14%) |
Gross Profit | $51,401,000,000 (-5.57%) | $54,431,000,000 (-0.13%) | $54,502,000,000 (4.57%) | $52,120,000,000 (6.27%) |
Operating Income | $8,516,000,000 (-38.03%) | $13,743,000,000 (72.78%) | $7,954,000,000 (-40.24%) | $13,310,000,000 (-4.32%) |
CVS Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | -$7,613,000,000 (63.55%) | -$20,889,000,000 (-313.89%) | -$5,047,000,000 (4.07%) | -$5,261,000,000 (4.93%) |
Net Cash Flow from Financing | -$1,135,000,000 (-142.30%) | $2,683,000,000 (125.51%) | -$10,516,000,000 (7.40%) | -$11,356,000,000 (-47.56%) |
Net Cash Flow from Operations | $9,107,000,000 (-32.17%) | $13,426,000,000 (-17.01%) | $16,177,000,000 (-11.43%) | $18,265,000,000 (15.13%) |
Net Cash Flow / Change in Cash & Cash Equivalents | $359,000,000 (107.51%) | -$4,780,000,000 (-878.50%) | $614,000,000 (-62.74%) | $1,648,000,000 (-37.46%) |
Net Cash Flow - Business Acquisitions and Disposals | -$95,000,000 (99.43%) | -$16,612,000,000 (-1096.83%) | -$1,388,000,000 (-850.68%) | -$146,000,000 (-461.54%) |
Net Cash Flow - Investment Acquisitions and Disposals | -$4,838,000,000 (-268.19%) | -$1,314,000,000 (-29.20%) | -$1,017,000,000 (62.57%) | -$2,717,000,000 (11.53%) |
Capital Expenditure | -$2,781,000,000 (8.25%) | -$3,031,000,000 (-11.15%) | -$2,727,000,000 (-8.21%) | -$2,520,000,000 (-3.41%) |
Issuance (Repayment) of Debt Securities | $5,059,000,000 (-36.22%) | $7,932,000,000 (288.36%) | -$4,211,000,000 (54.56%) | -$9,267,000,000 (-63.35%) |
Issuance (Purchase) of Equity Shares | -$2,662,000,000 (-53.43%) | -$1,735,000,000 (41.17%) | -$2,949,000,000 (-637.16%) | $549,000,000 (107.95%) |
Payment of Dividends & Other Cash Distributions | -$3,373,000,000 (-7.69%) | -$3,132,000,000 (-7.74%) | -$2,907,000,000 (-10.74%) | -$2,625,000,000 (-0.04%) |
Effect of Exchange Rate Changes on Cash | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Share Based Compensation | $0 (0%) | $0 (0%) | $0 (0%) | $484,000,000 (21.00%) |
Depreciation Amortization & Accretion | $0 (0%) | $0 (0%) | $0 (0%) | $4,486,000,000 (1.01%) |
CVS Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | 13.80% (-9.21%) | 15.20% (-10.06%) | 16.90% (-5.06%) | 17.80% (-2.73%) |
Profit Margin | 1.20% (-47.83%) | 2.30% (76.92%) | 1.30% (-51.85%) | 2.70% (0.00%) |
EBITDA Margin | 2.50% (-35.90%) | 3.90% (56.00%) | 2.50% (-58.33%) | 6.00% (-6.25%) |
Return on Average Equity (ROAE) | 6.20% (-45.13%) | 11.30% (91.53%) | 5.90% (-45.87%) | 10.90% (2.83%) |
Return on Average Assets (ROAA) | 1.80% (-47.06%) | 3.40% (78.95%) | 1.90% (-44.12%) | 3.40% (9.68%) |
Return on Sales (ROS) | 2.50% (-35.90%) | 3.90% (56.00%) | 2.50% (-44.44%) | 4.50% (-4.26%) |
Return on Invested Capital (ROIC) | 7.50% (-35.90%) | 11.70% (67.14%) | 7.00% (-29.29%) | 9.90% (7.61%) |
Dividend Yield | 5.90% (90.32%) | 3.10% (29.17%) | 2.40% (26.32%) | 1.90% (-34.48%) |
Price to Earnings Ratio (P/E) | 12.23 (0.54%) | 12.17 (-57.05%) | 28.32 (66.67%) | 17 (36.35%) |
Price to Sales Ratio (P/S) | 0.15 (-46.48%) | 0.28 (-25.07%) | 0.38 (-18.67%) | 0.47 (39.94%) |
Price to Book Ratio (P/B) | 0.75 (-43.72%) | 1.33 (-22.42%) | 1.71 (-5.57%) | 1.81 (40.84%) |
Debt to Equity Ratio (D/E) | 2.35 (3.75%) | 2.26 (3.38%) | 2.19 (4.34%) | 2.1 (-9.53%) |
Earnings Per Share (EPS) | 3.67 (-43.45%) | 6.49 (97.26%) | 3.29 (-45.80%) | 6.07 (10.77%) |
Sales Per Share (SPS) | 296.12 (6.35%) | 278.43 (13.28%) | 245.78 (10.98%) | 221.46 (7.89%) |
Free Cash Flow Per Share (FCFPS) | 5.03 (-37.88%) | 8.09 (-21.10%) | 10.25 (-14.12%) | 11.94 (16.37%) |
Book Value Per Share (BVPS) | 60.02 (0.86%) | 59.5 (9.23%) | 54.47 (-4.30%) | 56.92 (7.37%) |
Tangible Assets Book Value Per Share (TABVPS) | 106.93 (6.33%) | 100.56 (5.28%) | 95.52 (0.91%) | 94.66 (3.24%) |
Enterprise Value Over EBIT (EV/EBIT) | 14 (16.67%) | 12 (-45.45%) | 22 (37.50%) | 16 (23.08%) |
Enterprise Value Over EBITDA (EV/EBITDA) | 14.49 (18.58%) | 12.22 (-43.83%) | 21.75 (86.07%) | 11.69 (19.36%) |
Asset Turnover | 1.48 (2.42%) | 1.45 (3.36%) | 1.4 (11.13%) | 1.26 (8.82%) |
Current Ratio | 0.81 (-5.37%) | 0.86 (-9.31%) | 0.94 (6.78%) | 0.89 (-2.64%) |
Dividends | $2.66 (9.92%) | $2.42 (10.00%) | $2.2 (10.00%) | $2 (0.00%) |
Free Cash Flow (FCF) | $6,326,000,000 (-39.14%) | $10,395,000,000 (-22.71%) | $13,450,000,000 (-14.58%) | $15,745,000,000 (17.25%) |
Enterprise Value (EV) | $132,318,919,184 (-21.55%) | $168,666,354,115 (-4.34%) | $176,323,576,529 (-13.99%) | $205,009,251,056 (22.46%) |
Earnings Before Tax (EBT) | $6,176,000,000 (-44.60%) | $11,149,000,000 (91.56%) | $5,820,000,000 (-44.83%) | $10,549,000,000 (8.22%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | $9,134,000,000 (-33.85%) | $13,807,000,000 (70.31%) | $8,107,000,000 (-53.77%) | $17,538,000,000 (2.59%) |
Invested Capital | $124,345,000,000 (2.58%) | $121,222,000,000 (6.63%) | $113,688,000,000 (-8.05%) | $123,636,000,000 (-8.55%) |
Working Capital | -$15,964,000,000 (-40.89%) | -$11,331,000,000 (-199.13%) | -$3,788,000,000 (51.43%) | -$7,799,000,000 (-38.08%) |
Tangible Asset Value | $134,620,000,000 (4.18%) | $129,222,000,000 (3.11%) | $125,322,000,000 (0.38%) | $124,852,000,000 (4.03%) |
Market Capitalization | $56,489,919,184 (-44.41%) | $101,613,354,115 (-17.02%) | $122,448,576,529 (-10.08%) | $136,177,251,056 (52.33%) |
Average Equity | $74,850,500,000 (1.52%) | $73,726,500,000 (1.28%) | $72,791,500,000 (-0.79%) | $73,369,250,000 (8.15%) |
Average Assets | $251,966,500,000 (1.76%) | $247,608,750,000 (7.35%) | $230,659,750,000 (-0.65%) | $232,165,000,000 (-0.12%) |
Invested Capital Average | $122,521,250,000 (4.12%) | $117,667,500,000 (1.60%) | $115,817,250,000 (-11.72%) | $131,192,500,000 (-4.60%) |
Shares | 1,258,407,645 (-2.21%) | 1,286,896,582 (-2.06%) | 1,313,966,912 (-0.46%) | 1,320,058,657 (0.85%) |
